Agio Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Agio Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 15 Products, $11.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Agio Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 15 Products, $11.9M Trade | TransData Nexus

Agio Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Respiratory & OTC Specialist · $11.9M Total Trade · DGFT Verified

Agio Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $11.9M across 15 products in 8 therapeutic categories. Based on 726 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Dexamethasone ($1.9M), Phenylephrine ($1.8M), Clotrimazole ($1.4M).

Agio Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Agio Pharmaceuticals Limited pharmaceutical export portfolio — 15 products across 8 therapeutic categories. Source: Indian Customs (DGFT).

Who is Agio Pharmaceuticals Limited? — Company Overview & Market Position

Agio Pharmaceuticals Limited, established in 1991, is a privately held Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U24239MH1992PLC065031. As of the latest available data, Agio Pharmaceuticals has an authorized capital of ₹60 million and a paid-up capital of ₹51.85 million. The company operates in the manufacturing sector, focusing on the production of pharmaceutical and medicinal products.

Agio Pharmaceuticals Limited has a diverse product portfolio encompassing 15 products across eight therapeutic categories. The company's total export value stands at $11.9 million USD, with 726 shipments recorded. The top five exported products include Dexamethasone ($1.9 million), Phenylephrine ($1.8 million), Clotrimazole ($1.4 million), Prednisolone ($1.3 million), and Salbutamol ($1.2 million). These products are primarily categorized under Respiratory & OTC (30.8%), Respiratory (21.4%), and Antifungals (19.4%). Notably, the top five products contribute to 64.4% of the company's total export value, indicating a moderate level of portfolio concentration.

What Does Agio Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Dexamethasone$1.9M

Product Portfolio — Top 15 by Export Value

Agio Pharmaceuticals Limited exports 15 pharmaceutical products across 8 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Dexamethasone	Corticosteroids	$1.9M	84	1.1%	13
2	Phenylephrine	Respiratory & OTC	$1.8M	103	2.1%	9
3	Clotrimazole	Antifungals	$1.4M	136	1.5%	13
4	Prednisolone	Respiratory	$1.3M	64	1.4%	15
5	Salbutamol	Respiratory	$1.2M	62	0.8%	11
6	Bromhexine	Respiratory & OTC	$849.1K	41	5.2%	5
7	Gentamicin	Antibiotics	$808.1K	44	1.6%	13
8	Guaifenesin	Respiratory & OTC	$781.2K	34	2.9%	5
9	Terbinafine	Antifungals	$512.1K	53	1.9%	11
10	Miconazole	Antifungals	$389.8K	26	2.0%	8
11	Salicylic	Combination Drugs	$281.8K	19	1.7%	10
12	Ambroxol	Respiratory & OTC	$241.6K	14	1.6%	14
13	Secnidazole	Advanced Antibiotics	$150.7K	12	0.5%	14
14	Ivermectin	Antimalarial & Antiparasitic	$138.0K	25	1.6%	13
15	Praziquantel	Antimalarial & Antiparasitic	$72.5K	9	2.5%	8

Agio Pharmaceuticals Limited exports 15 pharmaceutical products across 8 therapeutic categories with a total export value of $11.9M. The top category is Respiratory & OTC (30.8% of portfolio), followed by Respiratory (21.4%), indicating a concentrated portfolio with the top 5 products accounting for 64.4% of total export value.

Agio Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Agio Pharmaceuticals Limited operates manufacturing facilities in Mumbai, Maharashtra. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details regarding plant capacities and certifications are not publicly disclosed, Agio Pharmaceuticals emphasizes adherence to Good Manufacturing Practices (GMP) guidelines to ensure product quality and safety.

3Key Leadership

The leadership team at Agio Pharmaceuticals Limited includes:

Madhusudan Ruia: Whole Time Director
Pankaj Nandkishor Chandak: Whole Time Director
Sunil Rajaram Rane: Whole Time Director
Anjanikumar Anilkumar Pandey: Managing Director

These executives play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Agio Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Agio Pharmaceuticals Limited's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available sources. The company focuses on global pharmaceutical marketing, with a presence in over 40 countries. However, specific regulatory filings, approvals, and market access statuses in these regions are not publicly disclosed.

2Emerging Markets

Agio Pharmaceuticals Limited has expanded its footprint into emerging markets, including Africa, Latin America, and Southeast Asia. The company's dedicated regulatory experts facilitate compliance with various international regulatory formalities, enabling entry into these markets. While the company has established subsidiaries in Kazakhstan, the Philippines, and Dubai, specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly available.

3Geographic Strategy

Agio Pharmaceuticals Limited demonstrates a diversified geographic strategy by establishing subsidiaries in multiple countries, including Kazakhstan, the Philippines, and Dubai. This approach mitigates concentration risk and allows the company to adapt to local market dynamics. The strategic direction appears to focus on expanding global reach while maintaining a strong presence in the domestic market of India.

Agio Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Agio Pharmaceuticals Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's focus on global pharmaceutical marketing suggests potential interactions with regulatory bodies such as the FDA; however, explicit information is not available.

2WHO & EU GMP

While Agio Pharmaceuticals Limited emphasizes adherence to GMP guidelines, specific certifications such as WHO prequalification or EU GMP certificates are not publicly disclosed. The company's commitment to quality is evident through its operational practices, but detailed certification statuses remain unspecified.

3CDSCO & Indian Regulatory

Agio Pharmaceuticals Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has approvals from state drug controllers in India. The company also possesses export No Objection Certificates (NOCs), facilitating its international trade activities. These regulatory compliances underscore the company's commitment to maintaining high standards in pharmaceutical manufacturing and distribution.

Agio Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Agio Pharmaceuticals Limited operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share comparisons and head-to-head analyses are not publicly available, the company's diverse product portfolio and global presence position it as a notable entity in the market. The emphasis on ethical and over-the-counter medicines, herbal formulations, and veterinary products allows Agio Pharmaceuticals to cater to a wide range of therapeutic needs.

2Key Differentiators

Agio Pharmaceuticals Limited's key differentiators include its diversified product portfolio spanning 15 products across eight therapeutic categories and its global presence in over 40 countries. The establishment of subsidiaries in markets such as Kazakhstan, the Philippines, and Dubai enhances its ability to adapt to local market dynamics and regulatory environments. The company's commitment to quality is reflected in its adherence to GMP guidelines and its focus on ethical and over-the-counter medicines, herbal formulations, and veterinary products.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Agio Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Agio Pharmaceuticals Limited demonstrates a strong track record in pharmaceutical manufacturing, with a total export value of $11.9 million USD and 726 shipments recorded. The company's portfolio includes 15 products across eight therapeutic categories, indicating a diversified and consistent supply capability. The establishment of subsidiaries in various countries suggests a reliable and adaptable supply chain, capable of meeting international demand.

2Certifications to Verify

Importers should verify the following certifications when engaging with Agio Pharmaceuticals Limited:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify adherence to World Health Organization Good Manufacturing Practices to ensure product quality and safety.

Frequently Asked Questions — Agio Pharmaceuticals Limited

How many pharmaceutical products does Agio Pharmaceuticals Limited export from India?

Agio Pharmaceuticals Limited exports 15 pharmaceutical products across 8 therapeutic categories. The top exports are Dexamethasone ($1.9M), Phenylephrine ($1.8M), Clotrimazole ($1.4M), Prednisolone ($1.3M), Salbutamol ($1.2M). Total export value is $11.9M.

What is Agio Pharmaceuticals Limited's total pharmaceutical export value?

Agio Pharmaceuticals Limited's total pharmaceutical export value is $11.9M, based on 726 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Agio Pharmaceuticals Limited cover?

Agio Pharmaceuticals Limited exports across 8 therapeutic categories. The largest are Respiratory & OTC (30.8%, 4 products), Respiratory (21.4%, 2 products), Antifungals (19.4%, 3 products).

Get Full Agio Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.